INTRODUCTION & OBjECTIVE
• Germany and Scotland are arguably among the first countries that manufacturers submit their evidence to obtain reimbursement.
• In Germany, with the introduction of the new AMNOG (Arzneimittelmarktneuordnungsgesetz) law on January 2011, the pricing regulations for newly authorized pharmaceuticals and their reimbursement by statutory health insurance providers has altered.
o There are three main governmental stakeholders in the AMNOG process: the Institute for Quality and Efficiency in Health Care (IQWiG) 1 , the Federal Joint Committee (G-BA) 2 and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) 3 . o Pharmaceuticals obtaining marketing authorization from European Medicines Association or the German Federal Institute for Drugs and Medical Device (BfArM) are automatically reimbursed by GKVSpitzenverband until the final benefit assessment decision is made by IQWIG and G-BA. This may take more than a year. o IQWIG reviews the AMNOG submissions by the manufacturers and provides an advice on the added value of the drug to G-BA which makes the final decision
The list price is still freely set by the manufacturer upon launch. Nevertheless, a commonly undisclosed price discount or reference pricing for the statutory health insurance providers is agreed after negotiations with the GKV-Spitzenverband on the grounds of the clinical benefit assessment outcomes 3 .
• The Scottish Medicines Consortium (SMC), established in 2001, ensures equal access and availability of medicines in Scotland by identifying and recommending the reimbursement of products with good value for money 4 . o
The SMC evaluates the submission on the grounds of the effectiveness, economic evaluation outcomes, the target population and the alternative available treatments
The drug price is fixed by the manufacturer and the SMC decides whether to accept or reject to recommend the product's reimbursement at the requested price. 
METHODS
• All AMNOG appraisal decisions made in 2011-2012 were identified (see poster PHP36).
• Only the final clinical benefit assessment made by G-BA was taken into account for this study 2 .
• Under AMNOG, the benefit assessment is performed for every available subpopulation and the outcome may be different for each of them. However, for the purpose of this study, the most positive outcome was selected and taken into consideration as the final benefit outcome for the whole product.
• In principle, outcomes in terms of price rebate negotiations are provided on the website of the GKVSpitzenverband. However, none of the manufacturers allowed for the rebate to be disclosed. Hence, a general web-search was conducted to identify price rebates.
• The SMC website 4 was searched to identify all reimbursement decisions for the same period of time. However, there were cases where the appraisal process of some products commenced later In Scotland than in Germany. Hence, the SMC website was hand searched to identify appraisal decisions made post December 2012.
• All matching AMNOG-SMC cases were identified and compared in terms of clinical benefit assessment and reimbursement decisions.
DISCUSSION
• AMNOG and SMC have their own analytical framework to decide upon a reimbursement and/or recommendation. This may lead to different outcomes for the same product in Germany and Scotland, respectively.
o
The list price of a product is still freely set by the manufacturer upon launch and the patients can freely get access to it until the final benefit assessment. When the benefit assessment is completed, AMNOG final prices may resemble generic prices for products that demonstrate a minor additional benefit. This can lead manufacturers to reconsider the launch of their product in Germany, depriving patients and clinicians from further access to the product. In comparison, a negative decision by SMC warrants re submission and re assessment of the set price for successful drug reimbursement which provokes delays to the marketing of the product in Scotland and consequently, a potentially delayed access to the product.
• Cost-effectiveness analysis is a crucial factor influencing the SMC reimbursement decision 6 . SMC appears to reject reimbursement on the grounds of cost-effectiveness, irrespective of whether the product is indicated for an orphan disease or not. o In Scotland, there is no defined policy for orphan drugs and these are evaluated as normal products. Hence, a high probability of an orphan drug indicating high cost effectiveness outcomes may be a hurdle for manufacturers to launch in Scotland. o In Germany however, the additional benefit for orphan products is presumed by IQWiG and G-BA and price negotiation starts automatically if annual sales do not exceed €50 million 7 .
• This study was limited to only publicly available information. Contextual factors such as the social, economic, health care and political environments as well as the constraints imposed by history and institutional frameworks were also not incorporated in this study.
• It would be ideal to extend this research by including more countries. International comparison may contribute to a better understanding of the implications that different pricing and reimbursement policies may have on the global market access environment.
RESULTS

Cases
• From January 2011 to December 2012, 41 G-BA decisions, covering 66 subgroups, and 129 SMC cases were identified.
• Twenty-four matching cases were compared, as these were assessed by both G-BA and SMC.
• The 24 common cases along with the clinical benefit assessment outcome and the reimbursement decision are presented in Table 1 and Table 2 , respectively.
AMNOG
• In 7 cases (29%) the G-BA acknowledged considerable benefit, in 9 cases (38%) minor additional benefit, in two cases (8%) the benefit was not quantifiable and in 6 cases (25%) the submitted evidence was not sufficient for a benefit to be demonstrated (no proof of benefit) .
• For the 21 cases, the price negotiations were completed, while for the remaining 3 the process was still on-going. o For 17 products (81%) the negotiations led to an agreed refund amount. For 1 case (5%) negotiations did not result in an agreement, hence the price was set by an arbitration board (fixed reimbursed amount) 3 . Finally, in 3 cases (14%) no amount was defined as the manufacturer decided not to launch the product in Germany (i.e. opt-out).
o It seems that a positive list is created in Germany, as none of the assessed products were rejected for reimbursement.
• The negotiated price rebate was available only for 8 cases 5 . On the grounds of the benefit assessment, the negotiated price rebates ranged from 4.7% to 29.7% based on manufacturer set price 5 .
• Of the 41 identified AMNOG cases, 7 products were labelled as orphan drugs. Only one of the orphan drugs was assessed by both G-BA and SMC; the remaining six were not assessed by SMC and excluded from this study.
SMC
• In SMC, a product of interest can demonstrate superiority, non-inferiority or inferiority over the comparator. The SMC acknowledged superior benefit in 15 cases (63%) and therapeutic equivalence in the remaining 9 cases (37%).
• The SMC recommended to reimburse 16 products (67%), of which 6 (38%) were restricted to a specific population or time period. SMC rejected 8 cases (33%) based on weak economic evidence. For 4 of the restricted products, the restriction was related to the cost effectiveness outcomes.
Comparing AMNOG versus SMC
• Both G-BA and SMC reached the same clinical benefit assessment in only 11 cases (46%) with the AMNOG implementing a more rigorous process with respect to clinical evidence assessment compared to SMC.
• The G-BA accepted to reimburse all assessed products, while evidently SMC can reject to recommend a product for reimbursement or restrict its use to a certain population if they assess no value for money. • Finally, it was observed that the SMC assessment process starts either at the same time or a few months later than the AMNOG process. 
